Back to search results

Genetic Influences on Late Onset Alzheimer's Disease Risk

This observational study is looking for 10,000 people to understand the genetic factors that increase the risk of Alzheimer's disease (AD). Researchers believe that certain genes, beyond those already known, might play a role in AD risk within families. You might be eligible if you are 55 or older, have an established diagnosis of AD or a related neurodegenerative disorder like Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD), or if you have a close family member with AD. The study involves a Blood Draw (for genetic testing) and a Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test (a memory test). The main goal is to identify new genes linked to AD risk over a 5-year period. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll 10,000 participants. It aims to identify genes associated with Alzheimer's disease risk.
What's involved
You would provide blood samples for genetic testing and complete a memory test.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the total number of genes identified to be associated with AD risk at 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05010603

Late Onset Alzheimer's Disease

Recruiting
Not specifiedAges 55+Observational
Columbia University
~10,000 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Blood DrawLate Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

At a glance

Recruiting sites
12 of 12 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total number of genes identified to be associated with the risk of AD
Measured over 5 years

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's DiseaseFrontotemporal DementiaLewy Body Dementia

Where it's being run

12 sites across 11 states
Indiana2
District of Columbia1
Florida1
Illinois1
Minnesota1
Missouri1
New York1
North Carolina1

Study leadership

  • Richard P. Mayeux, MD, MSc · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Dolly Reyes-Dumeyer
[email protected]
212-305-5953
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases.
a living sibling with probable or possible AD;
a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older);
participants in the proband's generation with an identified companion serving as an informant;
participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent.

Exclusion

failure to identify an appropriate informant;
uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder;
discovery of additional diagnosis that could account for the clinical manifestations;
unwillingness to participate;
failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD);
participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.

What this trial measures

  • Total number of genes identified to be associated with the risk of AD5 years

    Genetic Linkage Analysis to Identify Genes Associated with the risk of Alzheimer's Disease: Identification of genes by performing genetic linkage analysis, in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease.